{"id":4198,"date":"2018-06-23T12:19:36","date_gmt":"2018-06-23T12:19:36","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=4198"},"modified":"2018-06-23T12:44:44","modified_gmt":"2018-06-23T12:44:44","slug":"controversias-y-debates-sobre-sociedad-y-pruebas-genomicas","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2018\/06\/23\/controversias-y-debates-sobre-sociedad-y-pruebas-genomicas\/","title":{"rendered":"Controversias y debates sobre sociedad y pruebas gen\u00f3micas"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2018\/04\/FDA.jpg\"><img loading=\"lazy\" class=\"alignleft wp-image-4157 size-full\" style=\"border-width: 1px;margin: 5px\" title=\"(c) FDA, 2018\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2018\/04\/FDA.jpg\" alt=\"FDA\" width=\"100\" height=\"85\" \/><\/a>Dos art\u00edculos abordan la reciente decisi\u00f3n de la <a title=\"Sitio de FDA\" href=\"http:\/\/www.fda.gov\">FDA<\/a> de autorizar la comercializaci\u00f3n de pruebas dirigidas al consumidor para el riesgo de <a title=\"Informaci\u00f3n sobre la enfermedad en OMIM\" href=\"http:\/\/omim.org\/entry\/114480\" target=\"_blank\">c\u00e1ncer de mama<\/a>, as\u00ed como de las pol\u00edticas con relaci\u00f3n a la cobertura de seguro m\u00e9dico para las pruebas gen\u00f3micas:<br \/>\n&#8211; <a title=\"JAMA. 2018;319(23):2377-2378. \" href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2682210\" target=\"_blank\">Direct-to-Consumer Genetic Testing The Implications of the US FDA\u2019s First Marketing Authorization for BRCA Mutation Testing<\/a><br \/>\n&#8211; <a title=\"JAMA. 2018;319(23):2379-2380. \" href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2678995\" target=\"_blank\">Evolving Payer Coverage Policies on Genomic Sequencing Tests Beginning of the End or End of the Beginning?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dos art\u00edculos abordan la reciente decisi\u00f3n de la FDA de autorizar la comercializaci\u00f3n de pruebas dirigidas al consumidor para el riesgo de c\u00e1ncer de mama, as\u00ed como de las pol\u00edticas con relaci\u00f3n a la cobertura de seguro m\u00e9dico para las pruebas gen\u00f3micas: &#8211; Direct-to-Consumer Genetic Testing The Implications of the US FDA\u2019s First Marketing Authorization [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[11,15,23],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4198"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=4198"}],"version-history":[{"count":3,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4198\/revisions"}],"predecessor-version":[{"id":4202,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4198\/revisions\/4202"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=4198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=4198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=4198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}